The report keeps ADD on Aster DM with a revised TP of INR 810, noting 24% YoY EBITDA growth, bed capacity expansion plans, and a cut in target multiple to 25x from 28x to reflect regulatory overhang.
Read this note →Aster DM Quality Care Limited
NSE ASTERDM BSE 540975 INE914M01019
0 filings · 0 analysed
732.00
+1.73%
over 5 days
-
HSIE Results Daily 07 Nov 26 HSIE
The report keeps ADD on Aster DM with a revised TP of INR 810, noting 24% YoY EBITDA growth, bed capacity expansion plans, and a cut in target multiple to 25x from 28x to reflect regulatory overhang.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 07 Nov 2026, 06:48 | long | 713.15 | 810.00 | — | — | open by 2027-11-07 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 680.30 | 900.00 | 713.15 | 15% | open by 2027-10-07 |
| Motilal Oswal Financial Services Ltd. | 29 Sep 2026, 08:49 | long | 733.95 | 910.00 | 713.15 | -12% | open by 2027-09-29 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report states an ADD rating on Aster DM.
Read this note →The report estimates a Sales/EBITDA impact of 0.6%/2.7% from the oncology drug price cap and maintains an ADD rating.
Read this note →The report flags numbers as not comparable due to the Quality Care Hospital merger, with strong reported growth but a cautious first integration quarter.
Read this note →The report expects Aster to deliver 1.2x/1.2x/1.6x YoY growth in sales/EBITDA/PAT owing to the merger with QCIL, and plans to add 634 beds in FY27.
Read this note →The note says it estimates a ~7% EBITDA impact for Aster DM and maintains BUY.
Read this note →The report initiates coverage on Aster DM Quality Care with a Buy rating and target price of INR 910, implying 22% upside, citing the Aster DM Healthcare-QCIL merger creating a scaled pan-India platform.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief